Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
157 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Chronic Heart Failure - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Chronic Heart Failure - Pipeline Review, H2 2014', provides an overview of the Chronic Heart Failure's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Heart Failure and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Chronic Heart Failure Overview 10 Therapeutics Development 11 Pipeline Products for Chronic Heart Failure - Overview 11 Pipeline Products for Chronic Heart Failure - Comparative Analysis 12 Chronic Heart Failure - Therapeutics under Development by Companies 13 Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes 15 Chronic Heart Failure - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Chronic Heart Failure - Products under Development by Companies 20 Chronic Heart Failure - Products under Investigation by Universities/Institutes 22 Chronic Heart Failure - Companies Involved in Therapeutics Development 23 Hospira, Inc. 23 Amgen Inc. 24 Sanofi 25 Novartis AG 26 Laboratoires Pierre Fabre SA 27 Les Laboratoires Servier SAS 28 Pfizer Inc. 29 Bayer AG 30 Celladon Corporation 31 Mesoblast Limited 32 Palatin Technologies, Inc. 33 AnGes MG, Inc. 34 MetrioPharm AG 35 Cyano Biotech GmbH 36 NormOxys, Inc. 37 Cardioxyl Pharmaceuticals, Inc. 38 PhaseBio Pharmaceuticals, Inc. 39 miRagen Therapeutics, Inc. 40 Fibrotech Therapeutics Pty. Ltd. 41 Otsuka Holdings Co., Ltd. 42 Zensun (Shanghai) Sci & Tech Co., Ltd. 43 Chronic Heart Failure - Therapeutics Assessment 44 Assessment by Monotherapy Products 44 Assessment by Combination Products 45 Assessment by Target 46 Assessment by Mechanism of Action 49 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 57 Neucardin - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 rivaroxaban - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 (sacubitril + valsartan) - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 CEP-41750 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 aliskiren fumarate - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 sildenafil citrate - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 ivabradine - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 PL-3994 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 omecamtiv mecarbil - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Mydicar - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 CXL-1020 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 serelaxin (recombinant) - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 tolvaptan - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 finerenone - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 ivabradine - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 F-373280 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 cenderitide - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 beperminogene perplasmid - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 OXY-111A - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 MGN-9103 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 BR-5489 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 FT-011 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 PB-1046 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 Cell Therapy for Chronic Heart Failure - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 SAR-296968 - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 etomoxir - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 Vestiras - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 Chronic Heart Failure - Recent Pipeline Updates 111 Chronic Heart Failure - Dormant Projects 145 Chronic Heart Failure - Product Development Milestones 146 Featured News & Press Releases 146 Apr 02, 2014: FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell's itMSC Therapy to Treat Dilated Chronic Heart Failure 146 Mar 31, 2014: PARADIGM-HF trial of Novartis' LCZ696 for chronic heart failure closes early based on strength of interim results 147 Nov 21, 2013: CHMP Adopts Positive Opinion For Servier's Corlentor 147 Oct 31, 2013: FDA Clears Commencement Of Phase III Chronic Heart Failure Trial Using Mesoblast's Proprietary Cells 148 Jun 18, 2013: PhaseBio Expands Clinical Development Of Vasomera For Cardiopulmonary Diseases 149 May 23, 2013: Zensun Announces Positive Clinical Results For Neucardin To Improve Heart Function And Reduce Mortality In Chronic Heart Failure Patients 149 Apr 11, 2013: Cardio3 BioSciences Announces Publication Of Positive Results From Phase II C-CURE Trial In Journal Of American College Of Cardiology 151 Mar 08, 2013: Bayer And Janssen Initiate New Pivotal Phase III Study Of Xarelto In Patients With Chronic Heart Failure And Significant Coronary Artery Disease 152 Mar 08, 2013: Janssen Launches EXPLORER Global Cardiovascular Research Program For Xarelto 153 Jan 22, 2013: Stealth Peptides Reports Successful Clinical Study Of Oral Bendavia 154 Appendix 156 Methodology 156 Coverage 156 Secondary Research 156 Primary Research 156 Expert Panel Validation 156 Contact Us 157 Disclaimer 157
List of Tables Number of Products under Development for Chronic Heart Failure, H2 2014 11 Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H2 2014 12 Number of Products under Development by Companies, H2 2014 14 Number of Products under Investigation by Universities/Institutes, H2 2014 15 Comparative Analysis by Late Stage Development, H2 2014 16 Comparative Analysis by Clinical Stage Development, H2 2014 17 Comparative Analysis by Early Stage Development, H2 2014 18 Comparative Analysis by Unknown Stage Development, H2 2014 19 Products under Development by Companies, H2 2014 20 Products under Development by Companies, H2 2014 (Contd..1) 21 Products under Investigation by Universities/Institutes, H2 2014 22 Chronic Heart Failure - Pipeline by Hospira, Inc., H2 2014 23 Chronic Heart Failure - Pipeline by Amgen Inc., H2 2014 24 Chronic Heart Failure - Pipeline by Sanofi, H2 2014 25 Chronic Heart Failure - Pipeline by Novartis AG, H2 2014 26 Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA, H2 2014 27 Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS, H2 2014 28 Chronic Heart Failure - Pipeline by Pfizer Inc., H2 2014 29 Chronic Heart Failure - Pipeline by Bayer AG, H2 2014 30 Chronic Heart Failure - Pipeline by Celladon Corporation, H2 2014 31 Chronic Heart Failure - Pipeline by Mesoblast Limited, H2 2014 32 Chronic Heart Failure - Pipeline by Palatin Technologies, Inc., H2 2014 33 Chronic Heart Failure - Pipeline by AnGes MG, Inc., H2 2014 34 Chronic Heart Failure - Pipeline by MetrioPharm AG, H2 2014 35 Chronic Heart Failure - Pipeline by Cyano Biotech GmbH, H2 2014 36 Chronic Heart Failure - Pipeline by NormOxys, Inc., H2 2014 37 Chronic Heart Failure - Pipeline by Cardioxyl Pharmaceuticals, Inc., H2 2014 38 Chronic Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2014 39 Chronic Heart Failure - Pipeline by miRagen Therapeutics, Inc., H2 2014 40 Chronic Heart Failure - Pipeline by Fibrotech Therapeutics Pty. Ltd., H2 2014 41 Chronic Heart Failure - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 42 Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2014 43 Assessment by Monotherapy Products, H2 2014 44 Assessment by Combination Products, H2 2014 45 Number of Products by Stage and Target, H2 2014 48 Number of Products by Stage and Mechanism of Action, H2 2014 51 Number of Products by Stage and Route of Administration, H2 2014 53 Number of Products by Stage and Molecule Type, H2 2014 56 Chronic Heart Failure Therapeutics - Recent Pipeline Updates, H2 2014 111 Chronic Heart Failure - Dormant Projects, H2 2014 145
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.